Artificial Pancreas Device Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The artificial pancreas device system market covers hardware, software, and consumables used in automated insulin delivery for diabetes management. These systems range from threshold-suspend devices to more advanced hybrid closed-loop platforms that adjust basal insulin in response to sensor glucose readings. With a 2025 valuation near USD 0.29 billion and a projected 16.33% CAGR, the market is on track to exceed USD 1 billion before 2032 according to DelveInsight's August 2025 estimate.

• •Base value of about USD 0.29 billion in 2025, with 16.33% projected CAGR through 2032
• •Some long-horizon forecasts place the category near USD 2.0 billion by 2035
• •Primary indication remains type 1 diabetes, with type 2 expansion under investigation

Rising diabetes prevalence, particularly type 1 diabetes in pediatric and young-adult populations, is expanding the addressable patient base. Reimbursement improvements for CGMs and insulin pumps in the U.S., Europe, and parts of Asia-Pacific are lowering out-of-pocket costs and accelerating adoption. At the same time, improvements in CGM accuracy, pump miniaturization, smartphone connectivity, and adaptive control algorithms are making closed-loop systems easier to prescribe and use.

• •Growing global diabetes burden is increasing demand for automated insulin delivery
• •Expanding insurance and public reimbursement coverage for CGM and insulin pumps
• •Faster, more accurate sensors and smarter algorithms improving real-world glycemic outcomes

By component, the market splits into insulin pumps, CGMs, control software, and consumables such as infusion sets and sensors; insulin pumps and CGMs typically account for the largest revenue share. By end user, hospitals, specialty diabetes clinics, and home-care settings drive demand, with home use growing fastest as systems become more consumer-friendly. Regionally, North America leads on the back of high diagnosis rates and reimbursement, Europe follows, and Asia-Pacific is the fastest-growing region as healthcare access improves.

• •Insulin pumps and CGMs are the largest revenue contributors among components
• •Home-care and outpatient settings represent the fastest-growing end-user segment
• •North America leads today, while Asia-Pacific is expanding at the highest growth rate

What are the recent trends and outlook?

The next phase of growth is being shaped by fully closed-loop systems that minimize mealtime announcements, broader use of smartphone apps as the primary user interface, and tighter integration between pumps, CGMs, and automated insulin-dosing software. Regulatory approvals are also extending into type 2 diabetes, which could meaningfully enlarge the patient pool beyond type 1 users. Over the medium term, payers and providers are expected to prioritize outcomes-based evidence on time-in-range and hypoglycemia reduction, which should further support reimbursement expansion.

• •Shift toward fully closed-loop and smartphone-controlled systems
• •Regulatory and clinical expansion into type 2 diabetes indications
• •Increasing reliance on real-world outcomes data to secure reimbursement and clinician uptake